# A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Source: https://onco.cc/trials/nct07570173/  
OnCo record `nct07570173` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing MK-1045 in acute lymphoblastic leukaemia, now recruiting.

## Summary

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukaemia (MK-1045-005) is a phase 2/3 interventional study registered as NCT07570173, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 2/3, Randomised, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukaemia (B-ALL). Planned enrolment is 340 participants (estimated). The study started in 2026-05-18 and primary completion is expected in 2033-10-18. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07570173
- Phase: 2/3
- Setting: A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Sponsor: Merck Sharp & Dohme
- Enrolled: 340

## Sources

- ClinicalTrials.gov NCT07570173: https://clinicaltrials.gov/study/NCT07570173

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [MK-1045](https://onco.cc/drugs/mk-1045/), [Siltuximab](https://onco.cc/drugs/siltuximab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07570173.json